 |
Parkinsons News: 273 headlines |
|
|||||
Celebrity Fight Night Video  |
||||||||
|
||||||||
|
||||||||
| Sources used by our Parkinsons News Channel Research Team: | ||||||||
| The New York Times, CNN, FOX, CBS, BBC, Mayo Clinic, Johns Hopkins Medicine, UCLA Medical Center, National Institute of Health, Stanford Hospital, Memorial Sloan- Kettering, Yale Cancer Center, Massachusetts General Hospital, Brigham and Women's Hospital, University of Michigan, M. D. Anderson Cancer Center, National Institute of Health, American Cancer Association, NBC, Reuters News, American College of Cardiology, Journal of the American Medical Association & 100's more | ||||||||
| Links | ||||||||
| Barrow Neurological Institute | ||||||||
| Archives |
Saturday
TNF Inhibition May Help Suppress Parkinson's Disease
J Neurosci 2006;37:9365-9375.
"In vitro and murine studies suggest that blockade of the pro-inflammatory cytokine tumor necrosis factor (TNF) attenuates the loss of dopaminergic neurons typical of Parkinson's disease.
Senior investigator Dr. Malu G. Tansey told Reuters Health that 'chronic inflammation has been implicated in contributing to development of several neurodegenerative diseases, but its role in Parkinson's disease has not been convincingly demonstrated and is still controversial.'
Dr. Tansey of the University of Texas Southwestern Medical School, Dallas and colleagues investigated if inhibiting the action of TNF could rescue dopamine neurons from progressive degeneration in different animal models of Parkinson's disease.
The researchers report in the September 13th issue of the Journal of Neuroscience that use of the engineered dominant-negative TNF compound XENP345 caused a 50% drop in dopamine neuron death in the substantia nigra of brains of rats injected with the oxidative neurotoxin 6-hydroxidopamine."
"Our results," continued Dr. Tansey, "suggest that there is a therapeutic window of time after a neurotoxic insult during which anti-TNF treatment may prevent progressive loss of dopamine- producing neurons and therefore possibly prevent or significantly delay onset or worsening of disease symptoms."
"Based on this pre-clinical work," she concluded, "we predict that if we could successfully introduce TNF inhibitors or a gene encoding a TNF inhibitor into a patient's brain to block TNF action, we may be able to prevent the excessive TNF signaling that contributes to dopamine neuron loss and development of Parkinsonian syndromes."
J Neurosci 2006;37:9365-9375.
"In vitro and murine studies suggest that blockade of the pro-inflammatory cytokine tumor necrosis factor (TNF) attenuates the loss of dopaminergic neurons typical of Parkinson's disease.
Senior investigator Dr. Malu G. Tansey told Reuters Health that 'chronic inflammation has been implicated in contributing to development of several neurodegenerative diseases, but its role in Parkinson's disease has not been convincingly demonstrated and is still controversial.'
Dr. Tansey of the University of Texas Southwestern Medical School, Dallas and colleagues investigated if inhibiting the action of TNF could rescue dopamine neurons from progressive degeneration in different animal models of Parkinson's disease.
The researchers report in the September 13th issue of the Journal of Neuroscience that use of the engineered dominant-negative TNF compound XENP345 caused a 50% drop in dopamine neuron death in the substantia nigra of brains of rats injected with the oxidative neurotoxin 6-hydroxidopamine."
"Our results," continued Dr. Tansey, "suggest that there is a therapeutic window of time after a neurotoxic insult during which anti-TNF treatment may prevent progressive loss of dopamine- producing neurons and therefore possibly prevent or significantly delay onset or worsening of disease symptoms."
"Based on this pre-clinical work," she concluded, "we predict that if we could successfully introduce TNF inhibitors or a gene encoding a TNF inhibitor into a patient's brain to block TNF action, we may be able to prevent the excessive TNF signaling that contributes to dopamine neuron loss and development of Parkinsonian syndromes."